Yeramian Patrick D's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Apr 19, 2023
- Accession no.
- 0000899243-23-011461
- Filed
- Apr 19, 2023, 7:45 PM ET
- Trade date
- Apr 17, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.51M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yeramian Patrick DCIK 0001358266 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Common Stock | MOption exerciseAcquired | +44,861 | $0.37 | +$16,598.57 | 253,278 | Direct | |
| Apr 17, 2023 | Common Stock | MOption exerciseAcquired | +4,718 | $6.88 | +$32,459.84 | 257,996 | Direct | |
| Apr 17, 2023 | Common Stock | SSaleDisposed | −49,279 | $30.53F2 | −$1,504,660.35 | 208,717 | Direct | |
| Apr 17, 2023 | Common Stock | SSaleDisposed | −300 | $30.94 | −$9,282 | 208,417 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Common Stock | MOption exerciseDisposed | −44,861 | $0.00 | $0 | 17,605 | Direct | |
| Apr 17, 2023 | Common Stock | MOption exerciseDisposed | −4,718 | $0.00 | $0 | 43,534 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.